Lisofylline

Drug Profile

Lisofylline

Alternative Names: A-802710; BL 194; CT-1501R; ProTec

Latest Information Update: 10 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Therapeutics
  • Developer DiaKine Therapeutics; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases
  • Class Adjuvants; Chemoprotectants; Nonsteroidal anti-inflammatories; Radiation-sensitising agents; Small molecules; Xanthines
  • Mechanism of Action Immunosuppressants; Interleukin 12 inhibitors; Lysophosphatidic acid acyltransferase inhibitors; STAT4 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Transplant rejection
  • Discontinued Acute lung injury; Chemotherapy-induced damage; Graft-versus-host disease; Mucositis; Neutropenia; Septic shock; Type 1 diabetes mellitus

Most Recent Events

  • 01 Sep 2014 The NIH completes a phase II trial in islet cell transplantation (Adjunctive treatment) in the US (NCT00464555)
  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 01 May 2014 The NIH completes a phase III trial in islet cell transplantation (Adjunctive treatment) in the US (NCT00434811)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top